<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1386">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01775800</url>
  </required_header>
  <id_info>
    <org_study_id>1207012494</org_study_id>
    <nct_id>NCT01775800</nct_id>
  </id_info>
  <brief_title>Treatment Modification to Reduce Symptom Burden in Hemodialysis</brief_title>
  <official_title>Treatment Modification and Symptom Burden in High-Risk Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Rogosin Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Rogosin Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many patients on hemodialysis experience high rates of symptom burden, such as pain,
      depression, anxiety and difficulty breathing.  This study seeks to reduce these symptoms by
      modifying the usual guidelines used to manage patients on hemodialysis.  For example, rather
      than trying to keep serum phosphorus below 5.5, patients enrolled in this study may have
      treatment goals of less than 6.5, in order to reduce the number of pills they need to take
      and potentially reduce harmful side effects.  Blood pressure and serum parathyroid hormone
      goals will also be modified, to see if these modifications help hemodialysis patients feel
      better.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>quality of life</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Symptoms and quality of life as measured by the Short Form-36 and Dialysis Symptom Index</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Treatment modification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will be treated to different targets of blood pressure, parathyroid hormone and serum phosphorus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive the usual hemodialysis care with no modifications</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment modification</intervention_name>
    <arm_group_label>Treatment modification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hemodialysis patient

          -  transplant ineligible

        Exclusion Criteria:

          -  dementia

          -  unable to answer questionnaires for any reason
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathaniel Berman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rogosin Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Rogosin Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathaniel Berman, M.D.</last_name>
      <phone>212-746-9766</phone>
      <email>nab2009@nyp.org</email>
    </contact>
    <investigator>
      <last_name>Nathaniel Berman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>January 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
